Accessibility links
Pfizer Faces Celebrex Fallout Pfizer is dealing with repercussions of a study linking its painkiller Celebrex to an increased risk of heart trouble. The company will stop airing its ads for the drug in response to a request from the Food and Drug Administration, which is mulling further action. Meanwhile, Pfizer's stock continued to sink on Wall Street. NPR's Snigdha Prakash reports.

Health Care

Pfizer Faces Celebrex Fallout

Heard on All Things Considered

Pfizer Faces Celebrex Fallout

Listen
  • Download
  • <iframe src="https://www.npr.org/player/embed/4236839/4236840" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

Pfizer is dealing with repercussions of a study linking its painkiller Celebrex to an increased risk of heart trouble. The company will stop airing its ads for the drug in response to a request from the Food and Drug Administration, which is mulling further action. Meanwhile, Pfizer's stock continued to sink on Wall Street. NPR's Snigdha Prakash reports.